# of Displayed Technologies: 2 / 2


Targeting β-catenin signaling in combination with EGFR TKI enhances progression free survival and overall survival of EGFR mutant NSCLC
TS-042666 — The discovery of a novel treatment for EGFR TKI drug resistance in NSCLC.
Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is one of the leading causes of cancer-related death. Substantial progress has been made in the management of NSCLC as several driver mutations have been identified in cell communication pathways involved in lung tumor…
  • College: College of Medicine (COM)
  • Inventors: Arasada, Rajeswara Rao; Carbone, David
  • Licensing Officer: Davis, Stewart

Immunomodulating agents engineered from Notch receptor ligand extracellular domains
TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Carbone, David; Dikov, Mikhail; Long, Nicholas; Sullivan, Brandon; Tchekneva, Elena
  • Licensing Officer: Davis, Stewart

Loading icon